Gilead Goes All in On Arcus Option Deal Totaling $725 Million - NewsBreak

Gilead Goes All in On Arcus Option Deal Totaling $725 Million. Gilead Sciences announced it had exercised its options to three of Arcus Biosciences' programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat. The two companies have also added a research collaboration deal. Arcus shares...